Náhlé zhoršení renálních funkcí u staršího pacienta na léčbě vancomycinem pro endokarditidu
Authors:
Hundie Tesfaye 1; Jiřina Lukášková 2; Jana Hořínková 3
Authors‘ workplace:
Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital
1; KlinLab, Prague, Czech Republic
2; Motol, nd Faculty of Medicine, Charles University, Prague, Czech Republic
2; Department of Internal Medicine Neratovice, Czech Republic
3
Published in:
Čas. Lék. čes. 2012; 151: 531-534
Category:
Case Report
Overview
Vancomycin je lékem volby u infekcí, které způsobil methicillin-rezistentní Staphylococcus aureus (MRSA). Může být také užíván profylakticky u pacientů s rizikem endokarditidy. Často je užíván v kombinaci s jinými antibakteriálními léky při léčbě endokarditidy. Lék je potenciálně nefrotoxický. Jinak souhlasné směrnice se liší v hodnocení plazmatických koncentrací vancomycinu. Kazuistika popisuje případ 72leté pacientky z kavkazské polulace, u které se rychle vyvinulo významné zhoršení při terapii vancomycinem v kombinaci s penicilinem pro endokarditidu, způsobenou Streptococcus pneumoniae.
Klíčová slova:
vancomycin, nefrotoxicita, starší pacient, endokarditida.
Sources
1. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother 1998; 42: 1303–1307.
2. Bailic GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Medical toxikology and averse drug experience 1998; 3: 376–386.
3. Cunha BA. Vancomycin. Med. Clin N Am 1995; 79: 817–831.
4. Frimat L. Renal failure due to vancomycin alone. Nephrology Dialysis Transplantation 1995; 10: 550–551.
5. Rybak M, Lombaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus reviw of the American Society of Health sytem Pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health System Pharm 2009; 66: 82–98.
6. Tobin CM, Darville JM, Tomson AH, et al. Vancomycin therapeutic drug monitoring : Is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire. J Antimicrob Chemother 2002; 50: 713–718.
7. Payne CJ, Carmichael SJ, Stearns AT, et al. Vancomycin Continuous Infusion as Prophylaxis for Vascular Surgery Ther Drug Monit 2009; 31: 786–788.
8. Jeffres MN, Isakow W, Dohert JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with heathcare-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107–1115.
9. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay DR. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother 1994; 33: 811–821.
10. Hermsen Ed, Hanson M, Sankaranarayanan J, et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9: 9–14.
11. Revilla A, López J, Vilacosta I, et al. Clinical and prognostic profile of patients with infective endocarditis who need urgent surgery. Eur Heart J 2007; 28: 65–71.
12. Levy JH, Marty AT. Vancomycin and averse drug reactions. Crit Care Med 1993; 21: 1107–1108.
13. Jariyawat S, Sekine T, Tekeda M, Apiwattanakul N, et al. The interaction and transport of ß-lactam antibiotics with the cloned rat renal organic anion transporter 1 JEPT 1999; 290: 672–677.
14. Rhee KY, Gardiner DF, Charles M. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis 2005; 40: 1705–1706.
15. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood islolates from 2001–2005. J Antimicrob Chemother 2007; 60: 788–794.
16. Wang G, Hindler JF, Ward KW, Bruckner DA. Increasing vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883–3886.
17. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138–2144.
18. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42: S35–S39.
19. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a Reevaluation in an era of increasing doses Antimicrob Agents and Chemother 2009; 53: 483–486.
20. MacGowan AP. Pharmacodynamics, Pharmacokinetics, and Therapeutic Drug Monitoring of Glycopeptides. Ther Drug Monit 1998; 20: 473–477.
21. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507–514.
22. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 2386–2392.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Papiledém a ischemický edém terče optiku
- Enterohemoragické kmeny Escherichia coli – nebezpečné novější patogeny
- Lymphogranuloma venereum
- Principy pro zacházení s lidským genetickým materiálem a genotypizační informací